{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:53:33Z","timestamp":1791874413704,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T00:00:00Z","timestamp":1531699200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1038\/s41401-018-0069-8","type":"journal-article","created":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T09:37:58Z","timestamp":1531733878000},"page":"1777-1786","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["EGFR-targeting, \u03b2-defensin-tailored fusion protein exhibits high therapeutic efficacy against EGFR-expressed human carcinoma via mitochondria-mediated apoptosis"],"prefix":"10.1038","volume":"39","author":[{"given":"Wen-Juan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Hua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Fang","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Su","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,16]]},"reference":[{"key":"69_CR1","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.humimm.2013.05.008","volume":"74","author":"J Jarczak","year":"2013","unstructured":"Jarczak J, Kosciuczuk EM, Lisowski P, Strzalkowska N, Jozwik A, Horbanczuk J, et al. Defensins: natural component of human innate immunity. Hum Immunol. 2013;74:1069\u201379.","journal-title":"Hum Immunol"},{"key":"69_CR2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.cytogfr.2014.12.005","volume":"26","author":"M Suarez-Carmona","year":"2015","unstructured":"Suarez-Carmona M, Hubert P, Delvenne P, Herfs M. Defensins: \u201cSimple\u201d antimicrobial peptides or broad-spectrum molecules? Cytokine Growth Factor Rev. 2015;26:361\u201370.","journal-title":"Cytokine Growth Factor Rev"},{"key":"69_CR3","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3389\/fimmu.2012.00249","volume":"3","author":"H Ulm","year":"2012","unstructured":"Ulm H, Wilmes M, Shai Y, Sahl HG. Antimicrobial host defensins-specific antibiotic activities and innate defense modulation. Front Immunol. 2012;3:249","journal-title":"Front Immunol"},{"key":"69_CR4","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.1111\/j.1742-4658.2011.08302.x","volume":"278","author":"A Cederlund","year":"2011","unstructured":"Cederlund A, Gudmundsson GH, Agerberth B. Antimicrobial peptides important in innate immunity. FEBS J. 2011;278:3942\u201351.","journal-title":"FEBS J"},{"key":"69_CR5","doi-asserted-by":"crossref","first-page":"58418","DOI":"10.18632\/oncotarget.11170","volume":"7","author":"Y Du","year":"2016","unstructured":"Du Y, Shang BY, Sheng WJ, Zhang SH, Li Y, Miao QF, et al. A recombinantly tailored beta-defensin that displays intensive macropinocytosis-mediated uptake exerting potent efficacy against K-Ras mutant pancreatic cancer. Oncotarget. 2016;7:58418\u201334.","journal-title":"Oncotarget"},{"key":"69_CR6","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/mi.2013.6","volume":"6","author":"CJ Kelly","year":"2013","unstructured":"Kelly CJ, Glover LE, Campbell EL, Kominsky DJ, Ehrentraut SF, Bowers BE, et al. Fundamental role for HIF-1alpha in constitutive expression of human beta defensin-1. Mucosal Immunol. 2013;6:1110\u201318.","journal-title":"Mucosal Immunol"},{"key":"69_CR7","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3109\/07357907.2010.543210","volume":"29","author":"J Winter","year":"2011","unstructured":"Winter J, Pantelis A, Reich R, Martini M, Kraus D, Jepsen S, et al. Human beta-defensin-1, -2, and -3 exhibit opposite effects on oral squamous cell carcinoma cell proliferation. Cancer Invest. 2011;29:196\u2013201.","journal-title":"Cancer Invest"},{"key":"69_CR8","doi-asserted-by":"publisher","first-page":"8542","DOI":"10.1158\/0008-5472.CAN-06-0294","volume":"66","author":"CQ Sun","year":"2006","unstructured":"Sun CQ, Arnold R, Fernandez-Golarz C, Parrish AB, Almekinder T, He J, et al. Human beta-defensin-1, a potential chromosome 8p tumor suppressor: control of transcription and induction of apoptosis in renal cell carcinoma. Cancer Res. 2006;66:8542\u201349.","journal-title":"Cancer Res"},{"key":"69_CR9","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/978-1-4939-6637-0_18","volume":"1529","author":"W Gan","year":"2017","unstructured":"Gan W, Schneidman D, Zhang N, Ma B, Nussinov R. Probing oligomerized conformations of defensin in the membrane. Methods Mol Biol. 2017;1529:353\u201362.","journal-title":"Methods Mol Biol"},{"key":"69_CR10","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.molimm.2008.11.004","volume":"46","author":"SK Bose","year":"2009","unstructured":"Bose SK, Gibson W, Bullard RS, Donald CD. PAX2 oncogene negatively regulates the expression of the host defense peptide human beta defensin-1 in prostate cancer. Mol Immunol. 2009;46:1140\u201348.","journal-title":"Mol Immunol"},{"key":"69_CR11","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1007\/s00018-005-4560-2","volume":"62","author":"N Papo","year":"2005","unstructured":"Papo N, Shai Y. Host defense peptides as new weapons in cancer treatment. Cell Mol Life Sci. 2005;62:784\u201390.","journal-title":"Cell Mol Life Sci"},{"key":"69_CR12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1146\/annurev-cellbio-111315-125349","volume":"32","author":"KO Schink","year":"2016","unstructured":"Schink KO, Tan KW, Stenmark H. Phosphoinositides in control of membrane dynamics. Annu Rev Cell Dev Biol. 2016;32:143\u201371.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"69_CR13","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.molimm.2006.11.026","volume":"45","author":"RS Bullard","year":"2008","unstructured":"Bullard RS, Gibson W, Bose SK, Belgrave JK, Eaddy AC, Wright CJ, et al. Functional analysis of the host defense peptide Human Beta Defensin-1: new insight into its potential role in cancer. Mol Immunol. 2008;45:839\u201348.","journal-title":"Mol Immunol"},{"key":"69_CR14","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.18632\/oncotarget.6520","volume":"7","author":"TK Phan","year":"2016","unstructured":"Phan TK, Lay FT, Poon IK, Hinds MG, Kvansakul M, Hulett MD. Human beta-defensin 3 contains an oncolytic motif that binds PI(4,5)P2 to mediate tumour cell permeabilisation. Oncotarget. 2016;7:2054\u201369.","journal-title":"Oncotarget"},{"key":"69_CR15","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1128\/MCB.00282-15","volume":"35","author":"AA Baxter","year":"2015","unstructured":"Baxter AA, Richter V, Lay FT, Poon IK, Adda CG, Veneer PK, et al. The tomato defensin TPP3 binds phosphatidylinositol (4,5)-bisphosphate via a conserved dimeric cationic grip conformation to mediate cell lysis. Mol Cell Biol. 2015;35:1964\u201378.","journal-title":"Mol Cell Biol"},{"key":"69_CR16","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/intimm\/dxn012","volume":"20","author":"I Nagaoka","year":"2008","unstructured":"Nagaoka I, Niyonsaba F, Tsutsumi-Ishii Y, Tamura H, Hirata M. Evaluation of the effect of human beta-defensins on neutrophil apoptosis. Int Immunol. 2008;20:543\u201353.","journal-title":"Int Immunol"},{"key":"69_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2174\/187152008783497055","volume":"8","author":"RG Shao","year":"2008","unstructured":"Shao RG, Zhen YS. Enediyne anticancer antibiotic lidamycin: chemistry, biology and pharmacology. Anticancer Agents Med Chem. 2008;8:123\u201331.","journal-title":"Anticancer Agents Med Chem"},{"key":"69_CR18","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.ejps.2012.09.002","volume":"47","author":"Q Ru","year":"2012","unstructured":"Ru Q, Shang BY, Miao QF, Li L, Wu SY, Gao RJ, et al. A cell penetrating peptide-integrated and enediyne-energized fusion protein shows potent antitumor activity. Eur J Pharm Sci. 2012;47:781\u201389.","journal-title":"Eur J Pharm Sci"},{"key":"69_CR19","doi-asserted-by":"crossref","first-page":"26322","DOI":"10.18632\/oncotarget.4709","volume":"6","author":"J Xu","year":"2015","unstructured":"Xu J, Liu XJ, Li L, Zhang SH, Li Y, Gao RJ, et al. An engineered TIMP2-based and enediyne-integrated fusion protein for targeting MMP-14 shows potent antitumor efficacy. Oncotarget. 2015;6:26322\u201334.","journal-title":"Oncotarget"},{"key":"69_CR20","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.phrs.2017.04.001","volume":"126","author":"J Xu","year":"2017","unstructured":"Xu J, Du Y, Liu XJ, Zhu BY, Zhang SH, Li L, et al. Recombinant EGFR\/MMP-2 bi-targeted fusion protein markedly binding to non-small-cell lung carcinoma and exerting potent therapeutic efficacy. Pharmacol Res. 2017;126:66\u201376.","journal-title":"Pharmacol Res"},{"key":"69_CR21","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1158\/1078-0432.CCR-09-2699","volume":"16","author":"XF Guo","year":"2010","unstructured":"Guo XF, Zhu XF, Shang Y, Zhang SH, Zhen YS. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity. Clin Cancer Res. 2010;16:2085\u201394.","journal-title":"Clin Cancer Res"},{"key":"69_CR22","doi-asserted-by":"publisher","first-page":"16075","DOI":"10.1074\/jbc.273.26.16075","volume":"273","author":"ML Poll van de","year":"1998","unstructured":"van de Poll ML, van Vugt MJ, Lenferink AE, van Zoelen EJ. Identification of the minimal requirements for binding to the human epidermal growth factor (EGF) receptor using chimeras of human EGF and an EGF repeat of Drosophila Notch. J Biol Chem. 1998;273:16075\u201381.","journal-title":"J Biol Chem"},{"key":"69_CR23","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s00262-014-1604-1","volume":"63","author":"WJ Liu","year":"2014","unstructured":"Liu WJ, Liu XJ, Li L, Li Y, Zhang SH, Zhen YS. Tuftsin-based, EGFR-targeting fusion protein and its enediyne-energized analog show high antitumor efficacy associated with CD47 down-regulation. Cancer Immunol Immunother. 2014;63:1261\u201372.","journal-title":"Cancer Immunol Immunother"},{"key":"69_CR24","doi-asserted-by":"publisher","first-page":"e92986","DOI":"10.1371\/journal.pone.0092986","volume":"9","author":"XF Guo","year":"2014","unstructured":"Guo XF, Zhu XF, Yang WC, Zhang SH, Zhen YS. An EGFR\/HER2-bispecific and enediyne-energized fusion protein shows high efficacy against esophageal cancer. PLoS ONE. 2014;9:e92986","journal-title":"PLoS ONE"},{"key":"69_CR25","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.canlet.2010.02.020","volume":"295","author":"G Zhong","year":"2010","unstructured":"Zhong G, Zhang S, Li Y, Liu X, Gao R, Miao Q, et al. A tandem scFv-based fusion protein and its enediyne-energized analogue show intensified therapeutic efficacy against lung carcinoma xenograft in athymic mice. Cancer Lett. 2010;295:124\u201333.","journal-title":"Cancer Lett"},{"key":"69_CR26","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1080\/10717544.2017.1410261","volume":"25","author":"J Xu","year":"2018","unstructured":"Xu J, Du Y, Liu WJ, Li L, Li Y, Wang XF, et al. Intensive fibrosarcoma-binding capability of the reconstituted analog and its antitumor activity. Drug Deliv. 2018;25:102\u201311.","journal-title":"Drug Deliv"},{"key":"69_CR27","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.jprot.2009.01.002","volume":"72","author":"N Droin","year":"2009","unstructured":"Droin N, Hendra JB, Ducoroy P, Solary E. Human defensins as cancer biomarkers and antitumour molecules. J Proteom. 2009;72:918\u201327.","journal-title":"J Proteom"},{"key":"69_CR28","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.18632\/oncotarget.23616","volume":"9","author":"YW Sun","year":"2018","unstructured":"Sun YW, Xu J, Zhou J, Liu WJ. Targeted drugs for systemic therapy of lung cancer with brain metastases. Oncotarget. 2018;9:5459\u201372.","journal-title":"Oncotarget"},{"key":"69_CR29","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.addr.2015.12.024","volume":"99","author":"R Wen","year":"2016","unstructured":"Wen R, Banik B, Pathak RK, Kumar A, Kolishetti N, Dhar S. Nanotechnology inspired tools for mitochondrial dysfunction related diseases. Adv Drug Deliv Rev. 2016;99:52\u201369.","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41401-018-0069-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-018-0069-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-018-0069-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:01:13Z","timestamp":1684616473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-018-0069-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,16]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["69"],"URL":"https:\/\/doi.org\/10.1038\/s41401-018-0069-8","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,16]]},"assertion":[{"value":"7 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}